Intercept Pharmaceuticals IPO Research Information

Intercept Pharmaceuticals IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Intercept Pharmaceuticals, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Intercept Pharmaceuticals	ICPT -	$13.00-$15.00	$15.00	$19.40	5 million	10/11/2012
Underwriter(s): BofA Merrill Lynch, Citigroup, Goldman Sachs
Co-Manager(s): Deutsche Bank Securities, BMO Capital Markets, Needham & Co., Oppenheimer & Co., Wedbush PacGrow Life Sciences, JMP Securities, Summer Street Partners
Industry: Health Care
Filing(s): Filed 2012-09-04

Intercept Pharmaceuticals Quote & Chart - Click for current quote - ICPT

About Intercept Pharmaceuticals (adapted from Intercept Pharmaceuticals prospectus):
They are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver disease utilizing our expertise in bile acid chemistry.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "ICPT" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.